Artículos por temáticas

Evolution of impulsive-compulsive behaviors and cognition in Parkinson's disease.

Erga AH, Alves G, Tysnes OB, Pedersen KF.

J Neurol. 2020 Jan;267(1):259-266. doi: 10.1007/s00415-019-09584-7. Epub 2019 Oct 18.

Dopamine D1 receptor agonism induces dynamin related protein-1 inhibition to improve mitochondrial biogenesis and dopaminergic neurogenesis in rat model of Parkinson's disease.

Mishra A, Singh S, Tiwari V, Bano S, Shukla S.

Behav Brain Res. 2020 Jan 27;378:112304. doi: 10.1016/j.bbr.2019.112304. Epub 2019 Oct 15.

Apathy as a behavioural marker of cognitive impairment in Parkinson's disease: a longitudinal analysis.

Martin GP, McDonald KR, Allsop D, Diggle PJ, Leroi I.

J Neurol. 2020 Jan;267(1):214-227. doi: 10.1007/s00415-019-09538-z. Epub 2019 Oct 15.

Delayed Clinical Manifestation of Parkinson's Disease Among Physically Active: Do Participants in a Long-Distance Ski Race Have a Motor Reserve?

Olsson TT, Svensson M, Hållmarker U, James S, Deierborg T.

J Parkinsons Dis. 2020;10(1):267-274. doi: 10.3233/JPD-191762.

The Effects of Computer-Based Cognitive Rehabilitation on Working Memory in Patients with Parkinson's Disease: A Systematic Review.

Svaerke K, Niemeijer M, Løkkegaard A.

J Parkinsons Dis. 2020;10(1):47-57. doi: 10.3233/JPD-191726.

Asymmetry of Periodic Leg Movements in Sleep (PLMS) in Parkinson's Disease.

Hermann W, Flemming T, Brandt MD, Langner S, Reichmann H, Storch A.

J Parkinsons Dis. 2020;10(1):255-266. doi: 10.3233/JPD-191667.

A Dual-Modal Attention-Enhanced Deep Learning Network for Quantification of Parkinson's Disease Characteristics.

Xia Y, Yao Z, Ye Q, Cheng N.

IEEE Trans Neural Syst Rehabil Eng. 2020 Jan;28(1):42-51. doi: 10.1109/TNSRE.2019.2946194. Epub 2019 Oct 8.

Long-Term Efficacy of Safinamide on Symptoms Severity and Quality of Life in Fluctuating Parkinson's Disease Patients

Cattaneo C, Jost WH, Bonizzoni E.

J Parkinsons Dis. 2020;10(1):89-97. doi: 10.3233/JPD-191765.

Technology-Based Objective Measures Detect Subclinical Axial Signs in Untreated, de novo Parkinson's Disease.

Di Lazzaro G, Ricci M, Al-Wardat M, Schirinzi T, Scalise S, Giannini F, Mercuri NB, Saggio G, Pisani A.

J Parkinsons Dis. 2020;10(1):113-122. doi: 10.3233/JPD-191758.

Parkinson's Disease and Fabry Disease: Clinical, Biochemical and Neuroimaging Analysis of Three Pedigrees

Gago MF, Azevedo O, Guimarães A, Teresa Vide A, Lamas NJ, Oliveira TG, Gaspar P, Bicho E, Miltenberger-Miltenyi G, Ferreira J, Sousa N.

J Parkinsons Dis. 2020;10(1):141-152. doi: 10.3233/JPD-191704.

Comparing No-Show Rates of Neurology Outpatients with and without Parkinson's Disease: A Real-World Assessment of the Parkinsonian Personality Profile

Bell JF, Wu Y, Sollinger AB, Muthukattil RJ, Ferrara JM.

J Parkinsons Dis. 2020;10(1):347-350. doi: 10.3233/JPD-191651.

The Transition from Standing to Walking Is Affected in People with Parkinson's Disease and Freezing of Gait.

Amundsen Huffmaster SL, Lu C, Tuite PJ, MacKinnon CD.

J Parkinsons Dis. 2020;10(1):233-243. doi: 10.3233/JPD-191649.

Apelin-36 mediates neuroprotective effects by regulating oxidative stress, autophagy and apoptosis in MPTP-induced Parkinson's disease model mice.

Zhu J, Gao W, Shan X, Wang C, Wang H, Shao Z, Dou S, Jiang Y, Wang C, Cheng B.

Brain Res. 2020 Jan 1;1726:146493. doi: 10.1016/j.brainres.2019.146493. Epub 2019 Oct 3.

Neuroprotective effects of lignan 7-hydroxymatairesinol (HMR/lignan) in a rodent model of Parkinson's disease

Giuliano C, Siani F, Mus L, Ghezzi C, Cerri S, Pacchetti B, Bigogno C, Blandini F.

Nutrition. 2020 Jan;69:110494. doi: 10.1016/j.nut.2019.04.006. Epub 2019 Apr 25.

Targeting UCH in Drosophila melanogaster as a model for Parkinson's disease

Thao DTP.

Front Biosci (Landmark Ed). 2020 Jan 1;25:159-167.